相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide
Giovanni Palladini et al.
ANNALS OF HEMATOLOGY (2009)
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
Giada Bianchi et al.
BLOOD (2009)
Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
D. Lebovic et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
Ashutosh D. Wechalekar et al.
HAEMATOLOGICA (2008)
Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables
James R. Anderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens
Maria Roussou et al.
LEUKEMIA & LYMPHOMA (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Induction of endoplasmic reticulum stress-induced β-cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide
Chang-jiang Huang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Long-term outcome-of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
Vaishali Sanchorawala et al.
BLOOD (2007)
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
Efstathios Kastritis et al.
HAEMATOLOGICA (2007)
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
Arnaud Jaccard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Impairment of the ubiquitin-proteasome pathway is a downstream endoplasmic reticulum stress response induced by extracellular human islet amyloid polypeptide and contributes to pancreatic β-cell apoptosis
Silvia Casas et al.
DIABETES (2007)
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2007)
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study
Asher A. Chanan-Khan et al.
BLOOD (2007)
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
Vaishali Sanchorawala et al.
BLOOD (2007)
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2007)
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
Angela Dispenzieri et al.
BLOOD (2007)
Endoplasmic reticulum stress associated with extracellular aggregates - Evidence from transthyretin deposition in familial amyloid polyneuropathy
Pedro Filipe Teixeira et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL
Giovanni Palladini et al.
BLOOD (2006)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
G Palladini et al.
BLOOD (2005)
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
G Palladini et al.
BLOOD (2004)
Therapy for immunoglobulin light chain amyloidosis: the new and the old
MA Gertz et al.
BLOOD REVIEWS (2004)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Quality control in the endoplasmic reticulum protein factory
R Sitia et al.
NATURE (2003)
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
A Dispenzieri et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2003)
Regulation of apoptosis by endoplasmic reticulum pathways
DG Breckenridge et al.
ONCOGENE (2003)
Molecular mechanisms of amyloidosis
G Merlini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy
HJ Lachmann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins
A Dispenzieri et al.
LANCET (2003)
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis
G Palladini et al.
CIRCULATION (2003)
Autologous stem cell transplantation for primary systemic amyloidosis
RL Comenzo et al.
BLOOD (2002)
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis
G Palladini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease
LM Dember et al.
ANNALS OF INTERNAL MEDICINE (2001)
Impaired proteasome function in Alzheimer's disease
JN Keller et al.
JOURNAL OF NEUROCHEMISTRY (2000)
分享论文
